Biohope has conducted several research projects using its technology, collaborating with hospitals, academic institutions, and partners.
We had always focused in communicating to the medical community our study results and key messages:
Results from IMBITRA clinical study have been presented at the 53rd SEN Congress 2023
Results from IMBITRA study of Immunobiogram in renal transplant patients in maintenance phase have been presented at the 53rd SEN Congress 2023, which took place in Palma de Mallorca on November 11th - 13th. [...]
Biohope presents results of novel IVD solution in Rheumatoid Arthritis at EULAR Congress 2023
Biohope has presented a poster with clinical study results of the novel ROS and Monocytes tests to measure in vitro the methotrexate response in early rheumatoid arthritis patients at the European Congress of Rheumatology [...]
52º Congreso de la Sociedad Española de Nefrología
Oral communication C Jimenez, D Valencia , Mo Lopez, Me Gonzalez, Ma Moreno, A De Santos, A Ortega, T Diez, I Portero, A Sánchez-fructuoso. “Caracterización de los parámetros del Immunobiogram, un nuevo método para la [...]
The TRANSBIO study demonstrates the usefulness of Immunobiogram® for predicting the response to different immunosuppressive treatments in transplant recipients
The results have been published in the high-impact journal Transplant immunology. TRANSBIO, a multicenter, international clinical study, has demonstrated the correlation of the in-vitro measurement of the patient's pharmacodynamic response to immunosuppressive drugs, using the [...]
Recent Publication by Biohope in Frontiers in Immunology.
The prestigious international journal, “Frontiers in Immunology”, has recently published a paper about the Immunobiogram technology, called “The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy” . Frontiers in Immunology is a leading journal in [...]
Biohope presents further results from the Transbio International Study at The Transplant Society Congress (TTS 2020)
The Transplant Society Congress took place from September 13th-16th, and gathered the latest science and innovations in the field of transplantation worldwide. More than 3,000 scientists, researchers and physicians representing over 130 countries attended [...]
Biohope at ISPOR Europe 2019
ISPOR is the leading scientific and educational organization for HEOR (Health Economics & Outcomes Research) and its use in healthcare decision-making. The ISPOR engages global leaders in the world-wide HEOR community, including policy makers, [...]
Biohope at the Mass General, one of the top ten hospitals in the USA.
Biohope presents the results of the TRANSBIO International Trial to key investigators at the Massachusetts General Hospital (Harvard University), with very positive assessment of the trial results. The TRANSBIO Trial is a landmark study [...]
Biohope presents TRANSBIO clinical study results at ESOT Congress 2019
Biohope validated its product IMMUNOBIOGRAM® (IMBG) in the TRANSBIO clinical study, that was satisfactorily concluded with the recruitment of nearly 200 patients from 9 international hospitals. The promising results were shown before KOLs and renowned [...]
Successful completion of TRANSBIO clinical study
Biohope, an R&D company dedicated to the development of precision medicine IVD tools for chronic inflammatory conditions, announces the completion of the TRANSBIO clinical study. The TRANSBIO clinical study has included nearly 200 patients [...]
Biohope Poster awarded at 2019 ATC
Our CEO Isabel Portero and medical director Teresa Díez are at ATC2019Boston presenting the results of BH-Pilot clinical study which demonstrate the use of Immunobiogram® in the personalization of immunosupresant therapy. We are proud [...]
Biohope presents a poster at BST18
Biohope have presented a poster in the framework of the BST (Basic Science in Transplantation) congress that took place from October 11th to 13th in Rotterdam: “IIMMUNOBIOGRAM®: a new immunological tool to personalize immunosuppressive therapy in [...]
BH-Pilot results will be presented in this October
Biohope will present a poster in the framework of the BST (Basic Science in Transplantation) congress that takes place from October 11th to 13th in Rotterdam. It shows the biotechnological principles of the IMMUNOBIOGRAM® (IMBG) [...]
Gaceta Médica, leading newspaper in health information, interviews Dra. Isabel Portero, CEO & Founder of BIOHOPE
"Closer to the personalization of renal transplant treatment. First study to evaluate the functionality of the IMMUNOBIOGRAM® to predict the immunosuppressive response." > Read More
First Patient in: TRANSBIO CLINICAL STUDY starts the recruitment
The TRANSBIO clinical study has started with inclusion of the first patient in the Hospital Puerta de Hierro (Madrid, Spain) on the 12th of June 2018, with Dr. José María Portoles as Principal Investigator. The University Hospital Puerta [...]
Biohope in Boston
Biohope is holding these days meetings in Boston with investors and companies for future collaborations in the development of the IMMUNOBIOGRAM®, cutting-edge technology in the treatment of chronic inflammatory diseases that will allow the personalization of [...]
Presentation of the promising final IMMUNOBIOGRAM® results coming from BH-Pilot clinical study
On Tuesday 3th of July at TTS 2018, the promising final IMMUNOBIOGRAM® results coming from BH-Pilot clinical study will be presented in a lunch&learn session by Dr. Julio Pascual, Head of Nephrology Department in Hospital del [...]
BIOHOPE in Biotech Investment Showcase 2018
The 2018 Biotech Investment showcase is the UK and Europe’s most focussed and leading-edge funding, investment and partnering forum in the biotech sector, hosting over 200 attendees. Biope will be at this important event [...]
BIOHOPE received the approval from the Ethics Committees for the TRANSBIO clinical study that will be developed in collaboration with 8 international hospitals
BIOHOPE recently received the approval of the TRANSBIO clinical study protocol and informed consents forms from the 8 Ethics Committees of the centres involved in the study. The study will be developed in collaboration with [...]
